HEALTHWAY MEDICAL CORPORATION LIMITED
(Company Registration Number: 200708625C**)**
(Incorporated in the Republic of Singapore)

(A) PROPOSED ISSUANCE OF NOTES – COMPLETION AND ISSUE OF T2 CN B

(B) THE PROPOSED ACQUISITION OF HEALTHWAY MEDICAL ENTERPRISES PTE. LTD. – COMPLETION

---

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the announcements dated 17 January 2017, 19 January 2017, 6 February 2017, 13 February 2017, 24 February 2017, 11 March 2017, 23 March 2017, 24 March 2017, 28 March 2017, 31 March 2017, 4 April 2017, 11 April 2017, 12 April 2017, 13 April 2017 and 21 April 2017 (collectively "**Notes Announcements**") and the circular to Shareholders dated 6 April 2017 ("**Circular**").*

The Board of Directors ("**Board**") of Healthway Medical Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the announcement released on 21 April 2017 regarding, *inter alia*, the receipt of shareholders' approval for the issuance of T2 CN B for a principal amount of S$60 million and the acquisition of Healthway Medical Enterprises Pte. Ltd. ("**HME**") ("**Acquisition**").

The Board wishes to update that the Acquisition has been completed today and accordingly HME has become a wholly-owned indirect subsidiary of the Company.

As all the Second Closing Conditions have been fulfilled, the Company and the Subscriber have proceeded to Completion and the Company has issued S$60 million in principal amount of T2 CN B to the Subscriber on 21 April 2017. Accordingly, the Company had on 21 April 2017, received S$60 million from the Subscriber.

Responsibility Statement

The Directors of the Company (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate, and that there are no material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly.

Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors of the Company has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, accurately reflected or reproduced in this announcement.

BY ORDER OF THE BOARD

Veronica Chan Wee Ping
President
21 April 2017

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.